-
公开(公告)号：US11352363B1
公开(公告)日：2022-06-07
申请号：US17479530
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Xuri Gao , Ruichao Shen , Yong He , Jiajun Zhang , Joseph D. Panarese , Hui Cao , Xuechao Xing , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20220162217A1
公开(公告)日：2022-05-26
申请号：US17479530
申请日：2021-09-20
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Xuri Gao , Ruichao Shen , Yong He , Jiajun Zhang , Joseph D. Panarese , Hui Cao , Xuechao Xing , Yat Sun Or
IPC: C07D487/10 , A61P31/14
Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US11040998B2
公开(公告)日：2021-06-22
申请号：US16593262
申请日：2019-10-04
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Xuechao Xing , Jiang Long , Peng Dai , Brett Granger , Jing He
Abstract: The present invention provides compounds represented by Formula I, or pharmaceutically acceptable salts, stereoisomers, solvates, hydrates or combination thereof, The invention also provides pharmaceutical compositions comprising these compounds and methods of using this compounds for treating FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10683279B2
公开(公告)日：2020-06-16
申请号：US15979128
申请日：2018-05-14
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Ruichao Shen , Jiang Long , Jun Ma , Xuechao Xing , Yong He , Brett Granger , Jing He , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D405/14 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/12
Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, ester, stereoisomer, tautomer, solvate, hydrate, or combination thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US10519191B2
公开(公告)日：2019-12-31
申请号：US14952526
申请日：2015-11-25
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Yat Sun Or , Ruichao Shen , Peng Dai , Jiang Long , Xuechao Xing , Guoqiang Wang
Abstract: The present invention relates to compounds of Formula (IA) and Formula (IB), and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9 and m are as defined herein, pharmaceutical compositions comprising these compounds and methods of use of these compounds for treating a TGR5 mediated disease or condition.
-
Patent Agency Ranking
86.发明申请公开(公告)号：US20190337923A1
公开(公告)日：2019-11-07
申请号：US16400529
申请日：2019-05-01
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Guoqiang Wang , Ruichao Shen , Brett Granger , Jing He , Xuechao Xing , Yong He , Jiang Long , Jun MA , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D413/14 , C07D417/14 , C07D409/14 , C07D405/14
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
-
公开(公告)号：US20190194245A1
公开(公告)日：2019-06-27
申请号：US16222380
申请日：2018-12-17
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yat Sun Or , Ruichao Shen , Jiang Long , Peng Dai , Xuechao Xing , Jing He
Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.
-
公开(公告)号：US10323060B2
公开(公告)日：2019-06-18
申请号：US15439303
申请日：2017-02-22
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Yat Sun Or , Xuechao Xing , Guoqiang Wang , Ruichao Shen , Jing He
IPC: A61K31/575 , A61K31/58 , C07J9/00 , C07J43/00
Abstract: The present invention provides compounds of Formula I: pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR and/or TGR5.
-
公开(公告)号：US20180362503A1
公开(公告)日：2018-12-20
申请号：US15988806
申请日：2018-05-24
Applicant: ENANTA PHARMACEUTICALS, INC.
Inventor： Brett Granger , Guoqiang Wang , Ruichao Shen , Jing He , Yong He , Xuechao Xing , Jun Ma , Jiang Long , Bin Wang , Yat Sun Or
IPC: C07D401/14 , C07D471/04 , C07D471/08
CPC classification number: C07D401/14 , C07D417/14 , C07D451/02 , C07D451/06 , C07D471/04 , C07D471/08
Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).
-
公开(公告)号：US20180291058A1
公开(公告)日：2018-10-11
申请号：US15948370
申请日：2018-04-09
Applicant: Enanta Pharmaceuticals, Inc.
Inventor： Guoqiang Wang , Yong He , Brett Granger , Xuechao Xing , Yat Sun Or
IPC: C07J41/00
Abstract: The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGRS modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use.The present invention relates to a process for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),
-
-
-
-
-
-
-
-
-
Search Results
93
records
(took 0.036 seconds)
